The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vabametkib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, phase 2, cohort-1 trial.
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals
 
Hye Ryun Kim
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - ABL Bio; AstraZeneca; MSD Oncology; Ono Pharmaceutical; Roche/Genentech; Yuhan
Research Funding - AstraZeneca (Inst); Yuhan (Inst)
 
Ji-Youn Han
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sankyo/UCB Japan; Janssen; Lantern Pharma; Merck; Novartis; Oncovix; Takeda
Research Funding - Pfizer; Roche
 
Yu Jung Kim
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridge Biotherapeutics (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Jin Hyoung Kang
No Relationships to Disclose
 
Ki Hyeong Lee
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson/Janssen; Lilly; MSD; Pfizer; Takeda; Yuhan
Research Funding - Merck
(OPTIONAL) Uncompensated Relationships - Roche
 
Gyeong-Won Lee
No Relationships to Disclose
 
Byoung Yong Shim
Consulting or Advisory Role - AstraZeneca; Guardant Health; J Ints Bio; Takeda
Research Funding - Yuhan
 
Young Saing Kim
No Relationships to Disclose
 
Jin-Soo Kim
No Relationships to Disclose
 
Yong Won Choi
No Relationships to Disclose
 
Yun-Gyoo Lee
No Relationships to Disclose
 
Yoon Ji Choi
Leadership - OncoMaster
Stock and Other Ownership Interests - OncoMaster
Research Funding - Johnson & Johnson/Janssen (Inst)
 
Santosh Nair
No Relationships to Disclose
 
Waseemulla Khan
No Relationships to Disclose
 
James ChihHsin Yang
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Takeda
 
Te-Chun Hsia
No Relationships to Disclose
 
Hanlim Moon
No Relationships to Disclose
 
Inyoung Kim
No Relationships to Disclose
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Lunit (Inst); Merck Sharp & Dohme (Inst)